6533b7d0fe1ef96bd125a538

RESEARCH PRODUCT

Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of carbamazepine and its main metabolites.

Birte JensenSebastian HärtterMarytza LealKlaus K. UngerHarald WeigmannChristoph Hiemke

subject

DrugAnalyteChromatographymedicine.diagnostic_testChemistrymedia_common.quotation_subjectMetabolitemedicine.medical_treatmentElectrophoresis CapillaryGeneral ChemistryCarbamazepineHigh-performance liquid chromatographyMicellar electrokinetic chromatographychemistry.chemical_compoundAnticonvulsantCarbamazepineTherapeutic drug monitoringmedicineHumansAnticonvulsantsDrug MonitoringChromatography High Pressure Liquidmedia_commonmedicine.drug

description

In carbamazepine (CBZ) therapy the concomitant monitoring of concentrations of CBZ and its metabolites is strictly recommended, primarily to avoid toxic side effects. Currently, clinical routine monitoring of CBZ is accomplished by high-performance liquid chromatography or immunological methods. In this study a micellar electrokinetic capillary chromatographic (MECC) method was developed for routine drug monitoring of CBZ and its main metabolites, carbamazepine 10,11-diol and carbamazepine 10,11-epoxide, in human serum or plasma samples. The MECC method enabled baseline separation of all analytes within 2.5 min. The assay revealed sufficient precision and sensitivity and the results of either an automated HPLC or the MECC chromatography assay were in good agreement (r=-0.97). The maximum deviation for CBZ was 0.26 microM.

yearjournalcountryeditionlanguage
1998-08-01Journal of chromatography. B, Biomedical sciences and applications
10.1016/s0378-4347(98)00169-8https://pubmed.ncbi.nlm.nih.gov/9698248